Hovione is going global with its manufacturing expansion, from New Jersey all the way to Portugal.
The CDMO announced last week it would put $170 million into expansions in Portugal, Ireland and NJ, in an effort to increase its global capacity by 25%. The move follows an ongoing effort since 2016 to expand.
In a press release, COO Jean-Luc Herbeaux said:
These investments reinforce our integrated specialized offer globally, providing our clients with a line of sight for their projects. Focus is placed on facilitating and speeding up the drug development cycle and launch, by providing API manufacturing, Particle Engineering and Tableting services in each site. Our strategy continues to be to grow organically via investments in our existing sites, which are designed for purpose. This reduces the complexity associated with the growth journey and allows us to focus our management attention on what counts most, i.e. guaranteeing that our clients go to market with quality, safe and effective medicines for their patients.
In New Jersey, Hovione will add a 31,215-square-foot building next to an already-existing facility in East Windsor. The move will bring commercial spray-drying capacity online by 2023, and further investments will help the company factor US-based manufacturing up through commercial stage.
In Ireland, an already-existing site in Cork will be upgraded to add highly-potent API production. That expansion is set to add another 100 jobs over the next three years as Hovione plans to add on to the already-existing workforce of around 200. The site has been in operation since 2009.
And in Portugal, Hovione will increase its chemical synthesis capacity for HPAPIs. The building will get a new commercial spray dryer, which takes a liquid stream and separates the solute as a solid and the solvent into a vapor. This enables the process to be fully automated and continuous.
‘Hovione is in it for life and what better way to manifest this than through expansion of our global capacity and capabilities. Our sustainable organic growth strategy will allow us to keep true to those values that have been guiding us for more than 60 years,’ CEO Guy Villax said in a press release.
The CDMO has 60 years of experience under its belt. There are four existing manufacturing sites in the US, China, Ireland and Portugal, and R&D labs in Lisbon, Portugal and New Jersey.
https://endpts.com/hovione-plots-global-expansion-project-looking-to-boost-capacity-on-both-sides-of-the-atlantic